Tarafenacin(SVT-40776) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.

Tarafenacin(SVT-40776) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.

TAPI-1 is a specific TACE(TNF-α-converting enzyme) inhibitor.

TAP-311 is a novel potent and selective CETP inhibitor with plasma IC50 of 62 nM.

TAOK inhibitor 63 is a novel potent, selective, ATP-competitive TAO Kinase (TAOK) inhibitor with IC50 of 19 and 39 nM against TAOK1 (MAP3K16) and TAOK2 (MAP3K17), respectively.

Tanomastat is an angiogenesis and Matrix Metalloproteinase inhibitor

Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR. Phase 2.

Tamsulosin hydrochloride((R)-(-)-YM12617;LY253351) is a selective α1 receptor antagonist.

Taminadenant is an adenosine receptor A2a antagonist..

TAM-IN-1 is a highly potent, macrocyclic inhibitor of Mer and Axl with Ki of <50 pM and 130 pM, respectively..

TAME hydrochloride is an inhibitor of anaphase-promoting complex (APC), which prevents its activation by Cdc20 and Cdh1.

Talabostat mesilate(PT-100; Val-boroPro) is an orally active, specific inhibitor of dipeptidyl peptidases(IC50=1 nM for DPP4), including tumor-associated fibroblast activation protein.

Talabostat (PT-100, Val-boroPro) is a potent, nonselective, orally available inhibitor of post-proline cleaving serine proteases with Ki of 0.18 nM for DPP4, also potently inhibits DPP8/9 (IC50=1.5/0.76 nM), FAP, DPP2 and some other DASH family enzymes.

TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1.

TAK1-IN-1 is a potent, selective, Type I (ATP-competitive, DFG-in) TAK1 inhibitor with Kd of 59 nM, a thienopyrimidine scaffold that serves as a good starting point for medicinal chemistry..

TAK-100 is a potent, selective and orally active inhibitor of DPP-4 with IC50 of 5.3 nM, shows no inhibition on DPP2/8/9..

TAK 1 inhibitor

TAI-95 (TAI 95) is a potent, orally abioavailable Hec1 inhibitor that disrupts Hec1-Nek2 protein interaction wide anti-cancer spectrum (GI50=14.29-73.65 nM, breast cancer cell lines).

T6167923 (T-6167923) is a small molecule inhibitor of MyD88-dependent signaling pathways, disrupts MyD88 homodimeric formation.

T5342126 is a potent, selective TLR4 inhibitor, inhibits LPS-induced NO production in RAW 264 macrophage cells with IC50 of 27.8 uM.

T5342126 hydrochloride is a potent, selective TLR4 inhibitor, inhibits LPS-induced NO production in RAW 264 macrophage cells with IC50 of 27.8 uM.

T-521 is a novel PLK1 PBD (Polo-box domain) inhibitor that specifically inhibits the PBD of PLK1 (IC50=1.22 uM), but not those of Plk2-3.

T-448 free base (T448) is a specific inhibitor of LSD1 enzyme activity, enhances H3K4 methylation in primary cultured rat neurons but has little impact on LSD1-GFI1B complex in human TF-1a erythroblasts.

T3D 959 (DB-959) is a potent, brain penetrant, orally active dual PPARδ/PPARγ agonist with EC50 of 19/297 nM, respectively.

T-3861174 is a novel small molecule prolyl tRNA synthetase (PRS) with binding IC50 of 2.3 nM.

T-3775440 is a novel potent, selecitve, irreversible LSD1 inhibitor with IC50 of 2.1 nM.

T-3764518 (T 3764518, T3764518) is a novel potent, orally active SCD1 inhibitor with binding IC50 of 4.7 nM for hSCD1.

T-226296 is a potent, selective, non-peptide antagonist of MCHR1 (Melanin-concentrating hormone receptor 1) with IC50 of 5.5 nM and 8.6 nM for human and rat MCHR1, respectively.

T-1840383 is a potent, ATP-competitive, dual c-Met/VEGFR-2 inhibitor with IC50 of 1.9, 7.7, 2.2 and 5.5 nM for c-Met, VEGFR1, 2 and 3, respectively.

T-155535 is a small molecule inhibitor that effectively inhibits the β-catenin/Tcf4 interaction with Ki of 21 uM in AlphaScreen assay.